Compugen Ltd. (NASDAQ:CGEN) – Equities research analysts at FBR & Co lowered their FY2016 earnings per share (EPS) estimates for shares of Compugen in a research note issued to investors on Tuesday. FBR & Co analyst V. Bernardino now expects that the firm will earn ($0.60) per share for the year, down from their previous forecast of ($0.56). FBR & Co also issued estimates for Compugen’s Q4 2016 earnings at ($0.15) EPS, FY2017 earnings at ($0.57) EPS, FY2018 earnings at $0.09 EPS and FY2020 earnings at ($0.13) EPS.

Compugen (NASDAQ:CGEN) last released its earnings results on Monday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.01. Compugen had a negative net margin of 261.77% and a negative return on equity of 29.33%.

Earnings History and Estimates for Compugen (NASDAQ:CGEN)

Separately, Zacks Investment Research raised shares of Compugen from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Tuesday, October 4th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $10.40.

Compugen (NASDAQ:CGEN) opened at 6.50 on Thursday. Compugen has a 52-week low of $4.32 and a 52-week high of $7.79. The company’s 50 day moving average is $6.13 and its 200-day moving average is $6.61. The firm’s market cap is $330.90 million.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Compugen by 12.4% in the second quarter. Vanguard Group Inc. now owns 740,047 shares of the company’s stock valued at $4,796,000 after buying an additional 81,729 shares in the last quarter. Morgan Stanley boosted its stake in Compugen by 1.9% in the third quarter. Morgan Stanley now owns 713,710 shares of the company’s stock valued at $4,496,000 after buying an additional 13,630 shares during the period. BlackRock Fund Advisors boosted its stake in Compugen by 4.6% in the third quarter. BlackRock Fund Advisors now owns 671,557 shares of the company’s stock valued at $4,231,000 after buying an additional 29,402 shares during the period. Rothschild Investment Corp IL boosted its stake in Compugen by 2.2% in the second quarter. Rothschild Investment Corp IL now owns 458,510 shares of the company’s stock valued at $2,971,000 after buying an additional 10,000 shares during the period. Finally, Stockman Asset Management bought a new stake in Compugen during the third quarter valued at $597,000. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

5 Day Chart for NASDAQ:CGEN

Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.